Expanded Access Use of Derazantinib for Patients With Locally Advanced, Inoperable or Metastatic iCCA Harbouring FGFR Genomic Alterations
Phase of Trial: Phase II
Latest Information Update: 17 Sep 2019
Price : $35 *
At a glance
- Drugs Derazantinib (Primary)
- Indications Cholangiocarcinoma
- Focus Expanded access; Therapeutic Use
- 17 Sep 2019 Status changed from planning to recruiting.
- 29 Aug 2018 New trial record
- 14 Aug 2018 According to a Basilea Pharmaceutica media release, the company expects to initiate this study in mid 2019.